PubRank

William J Bremner

Author PubWeight™ 71.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007 5.97
2 Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002 4.46
3 Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2004 3.02
4 Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006 2.57
5 Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004 2.39
6 Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 2007 2.27
7 Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006 2.08
8 The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007 1.53
9 Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. J Androl 2007 1.45
10 Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with low-dose human chorionic gonadotropin: a randomized, controlled trial. Fertil Steril 2012 1.44
11 Testosterone deficiency and replacement in older men. N Engl J Med 2010 1.39
12 Advances in male contraception. Endocr Rev 2008 1.39
13 Testosterone administration suppresses adiponectin levels in men. J Androl 2004 1.24
14 Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab 2005 1.21
15 Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab 2005 1.19
16 Serum testosterone assays--accuracy matters. J Clin Endocrinol Metab 2004 1.19
17 A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab 2004 1.13
18 Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab 2005 1.12
19 Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis 2006 1.06
20 Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab 2006 1.05
21 Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab 2008 1.05
22 Age-related analysis of inhibin A, inhibin B, and activin a relative to the intercycle monotropic follicle-stimulating hormone rise in normal ovulatory women. J Clin Endocrinol Metab 2004 1.05
23 Effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist on spermatogenesis and intratesticular steroid levels in normal men. J Clin Endocrinol Metab 2005 1.04
24 Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. J Androl 2004 1.00
25 Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men. J Clin Endocrinol Metab 2004 1.00
26 Drug insight: Recent advances in male hormonal contraception. Nat Clin Pract Endocrinol Metab 2006 0.96
27 Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. J Androl 2006 0.93
28 A new combination of testosterone and nestorone transdermal gels for male hormonal contraception. J Clin Endocrinol Metab 2012 0.93
29 Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J Clin Endocrinol Metab 2009 0.93
30 Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 2002 0.91
31 Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen. Contraception 2007 0.90
32 Regulation of testicular function in men: implications for male hormonal contraceptive development. J Steroid Biochem Mol Biol 2003 0.89
33 Preoperative supraphysiological testosterone in older men undergoing knee replacement surgery. J Am Geriatr Soc 2002 0.88
34 Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men. J Androl 2004 0.88
35 10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. J Androl 2006 0.86
36 Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 2004 0.86
37 Serum 17-hydroxyprogesterone strongly correlates with intratesticular testosterone in gonadotropin-suppressed normal men receiving various dosages of human chorionic gonadotropin. Fertil Steril 2007 0.85
38 Variability in sperm suppression during testosterone administration to adult monkeys is related to follicle stimulating hormone suppression and not to intratesticular androgens. J Clin Endocrinol Metab 2002 0.85
39 Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab 2004 0.84
40 Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am J Physiol Endocrinol Metab 2003 0.84
41 The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol 2008 0.83
42 Nanomilled oral testosterone plus dutasteride effectively normalizes serum testosterone in normal men with induced hypogonadism. J Androl 2007 0.83
43 Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. J Androl 2005 0.83
44 Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen. J Androl 2002 0.82
45 Higher testosterone levels are associated with increased high-density lipoprotein cholesterol in men with cardiovascular disease: results from the Massachusetts Male Aging Study. Asian J Androl 2007 0.81
46 Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial. J Clin Endocrinol Metab 2012 0.80
47 Elevated end-of-treatment serum INSL3 is associated with failure to completely suppress spermatogenesis in men receiving male hormonal contraception. J Androl 2007 0.80
48 Reproductive ageing and ovarian function: is the early follicular phase FSH rise necessary to maintain adequate secretory function in older ovulatory women? Hum Reprod 2004 0.80
49 Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol 2009 0.79
50 The male contraceptive regimen of testosterone and levonorgestrel significantly increases lean mass in healthy young men in 4 weeks, but attenuates a decrease in fat mass induced by testosterone alone. J Clin Endocrinol Metab 2003 0.79
51 Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism. J Androl 2010 0.78
52 Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism. J Androl 2011 0.78
53 Effects of occupational solvent exposure on reproductive hormone concentrations and fecundability in men. Am J Ind Med 2004 0.77
54 The role of quality improvement and patient safety in academic promotion: results of a survey of chairs of departments of internal medicine in North America. Am J Med 2011 0.77
55 DHEA and testosterone in the elderly. N Engl J Med 2007 0.77
56 The androgen receptor gene CAG repeat polymorphism does not predict increased risk of heart disease: longitudinal results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2006 0.76
57 Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. J Clin Endocrinol Metab 2002 0.75
58 Testicular fine-needle aspiration for the assessment of intratesticular hormone concentrations. Asian J Androl 2015 0.75
59 Testosterone tied to mental function. But questions about the benefits and risks of testosterone therapy persist. Health News 2004 0.75
60 The research community now and in the future: APM's recommendations for NIH priorities. Am J Med 2003 0.75
61 [Effect of injection of testosterone undecanoate and depot medroxyprogesterone acetate on the suppression of spermatogenesis]. Zhonghua Nan Ke Xue 2004 0.75
62 Long-term outcome studies of testosterone therapy in older hypogonadal men: waiting for Godot? Nat Clin Pract Endocrinol Metab 2008 0.75